Table 4.
Summary of best response.
| RECIST |
mRECIST |
|||||
|---|---|---|---|---|---|---|
| LeToHAIC group (%) | Lenvatinib group (%) | p-valuea | LeToHAIC group (%) | Lenvatinib group (%) | p-valuea | |
| CR | 0 | 0 (0) | – | 10 (14.1) | 0 (0) | <0.001 |
| PR | 42 (59.2) | 8 (9.3) | <0.001 | 38 (53.5) | 14 (16.3) | <0.001 |
| SD | 22 (31) | 54 (62.8) | <0.001 | 16 (22.5) | 48 (55.8) | <0.001 |
| PD | 7 (9.9) | 24 (27.9) | 0.005 | 7 (9.9) | 24 (27.9) | 0.002 |
| DCR | 64 (90.1) | 62 (72.1) | 0.005 | 64 (90.1) | 62 (72.1) | 0.005 |
| ORR | 42 (59.2) | 8 (9.3) | <0.001 | 48 (67.6) | 14 (16.3) | <0.001 |
a
Statistical significance was assessed with the Chi-square test.
CR, complete response; DCR, disease control rate; HAIC, hepatic arterial infusion chemotherapy; LeToHAIC, lenvatinib, toripalimab plus HAIC; mRECIST, modified Response Evaluation Criteria in Solid Tumors; NA, not assessable; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.